sanofi-aventis usa (all divisions)

What sanofi-aventis usa (all divisions) does

Sanofi US is the American operating subsidiary of Sanofi, a French multinational pharmaceutical company publicly traded on Euronext Paris (ticker: SAN). The US entity markets and distributes more than 600 million medication units annually through US manufacturing facilities and a portfolio of 40+ prescription products spanning immunology (Dupixent, Kevzara, Arava), oncology (Sarclisa, Jevtana, Zaltrap, Elitek, Eloxatin, Caprelsa, Clolar), rare blood disorders (ALTUVIIIO, Alprolix, Eloctate, Cablivi, Enjaymo, Qfitlia), rare diseases (Fabrazyme, Aldurazyme, Lumizyme, Nexviazyme, Xenpozyme, Cerezyme, Cerdelga), diabetes (Lantus, Toujeo, Admelog, Apidra, Soliqua, Tzield, Merilog), cardiovascular disease (Plavix, Multaq, Lovenox, Avapro, Avalide, Praluent), neurology (Lemtrada, Aubagio), transplant (Thymoglobulin), and vaccines (Beyfortus, MenQuadfi). Several flagship assets are co-developed with Regeneron (Dupixent, Kevzara) and AstraZeneca (Beyfortus), reinforcing the IP and commercial base.

The business model is prescription pharmaceutical sales, vaccine sales, specialty rare disease distribution, and generics (Winthrop brand), monetized through enterprise field sales, specialty pharmacies, wholesale distributors, and direct e-commerce channels including Vaccineshoppe.com and sanofishoppe.com. The company operates three dedicated customer service channels (prescription customer care, specialty care, and vaccines), a DSCSA-compliant supply chain built on TraceLink ProductTrack and Antares Track4, and patient support programs such as CareConnectPSS SMS. Recent regulatory milestones include first-in-class FDA approvals for Tzield in stage 3 type 1 diabetes (June 2026) and subcutaneous Sarclisa Escena via on-body injector (July 2026).

Sanofi US maintains an extensive US operating footprint with headquarters in Cambridge, MA and offices in Morristown, NJ, Boston, Philadelphia, and Jersey City. Wholly-owned subsidiaries include Sanofi Specialty Care, Sanofi Genzyme, Bioverativ, and Winthrop. The company pursues social impact programs under the Stemulate Growth umbrella (The Air We Share, Discovery Education STEM Careers Coalition, Students 2 Science, Just-A-Start, Geisinger REACH-HEI) and has received consecutive HBA Luminaries and HBA Rising Stars recognition through 2026. US-specific revenue is not disclosed; consolidated financials are reported at sanofi.com/en/investors.

Name

sanofi-aventis usa (all divisions)

Legal name

Sanofi US

Website

https://sanofi-aventis.us

Company type

Public

Founded year

2005

Operating status

Operating

Short description

Sanofi US markets and distributes 40+ prescription medicines and vaccines across immunology, oncology, rare diseases, diabetes, and cardiovascular care, serving US patients and healthcare providers with 600+ million medication units produced annually.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Oncology Specialty Pharmaceuticals (HLAIACAA), Travel & Tropical Disease Vaccines (HLAIAEAE), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Generic Hospital & Institutional Products (HLAIABAL), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

Keywords

• Prescription pharmaceuticals
• Vaccines distribution
• Rare disease therapies
• Immunology medicines
• Specialty pharmaceuticals

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Prescription Pharmaceuticals: Sanofi generates revenue through prescription pharmaceuticals across multiple therapeutic areas including immunology (Dupixent, Kevzara), oncology (Sarclisa, Jevtana, Zaltrap), rare blood disorders (Alprolix, Eloctate, Altuviio, Qfitlia), diabetes (Admelog, Apidra, Lantus, Toujeo, Soliqua), and cardiovascular diseases.
2. Vaccines: Revenue from vaccine products including influenza vaccines and respiratory syncytial virus (RSV) vaccines distributed through Vaccineshoppe.com and healthcare providers.
3. Rare Disease Specialty Care: Specialty pharmaceutical products for rare diseases including Fabrazyme, Aldurazyme, Lumizyme, Xenpozyme, Enjaymo, and Tzield, provided through specialty care customer service at 1-800-745-4447.
4. Consumer Health/Generic Products: Products under Winthrop brand for generics distribution.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Core offering

Sanofi US develops, manufactures, and markets prescription pharmaceuticals and vaccines across multiple therapeutic areas including immunology, oncology, rare blood disorders, rare diseases, diabetes, cardiovascular disease, neurology, and transplant. The company sells these products through field sales representatives to healthcare professionals, specialty pharmacies, and authorized wholesale distributors, supported by U.S. manufacturing operations producing more than 600 million medication units annually.

Product overview

Sanofi is a diversified pharmaceutical company offering a broad portfolio of prescription medicines across multiple therapeutic areas including diabetes (Lantus, Toujeo, Admelog, Apidra, Soliqua, Tzield), cardiovascular disease (Plavix, Multaq, Lovenox, Avapro, Avalide, Praluent), immunology (Dupixent, Kevzara, Arava), neurology (Lemtrada, Aubagio), oncology (Sarclisa, Jevtana, Zaltrap, Elitek, Eloxatin, Caprelsa), rare blood disorders (ALTUVIIIO, Alprolix, Eloctate, Cablivi, ENJAYMO, Qfitlia), rare diseases (Aldurazyme, Fabrazyme, Lumizyme, Nexviazyme, Xenpozyme, Cerezyme, Cerdelga), vaccines (Beyfortus, MenQuadfi), and transplant (Thymoglobulin, Thyrogen). The company also operates community-focused health education programs including Stemulate Growth and The Air We Share.

Differentiator

Problem solved

Functional benefit

Brands

• Toujeo: Insulin glargine injection 300 Units/mL
• Soliqua 100/33
• Dupixent
• Kevzara
• Sarclisa
• Tzield
• Beyfortus
• MenQuadfi
• Cablivi
• Nexviazyme
• Xenpozyme
• Enjaymo
• Qfitlia
• ALTUVIIIO
• Alprolix
• ELOCTATE

Products and services

• Dupixent (dupilumab) Injection Monoclonal antibody injection for atopic dermatitis and other immunology conditions; co-developed with Regeneron.
• Kevzara (sarilumab) Injection Monoclonal antibody injection for rheumatoid arthritis; co-developed with Regeneron.
• Arava (leflunomide) tablets Disease-modifying antirheumatic drug for rheumatoid arthritis.
• Sarclisa (isatuximab-irfc) Anticancer monoclonal antibody for multiple myeloma; now available in subcutaneous formulation via on-body injector.
• Jevtana (cabazitaxel) Injection Anticancer chemotherapy for metastatic castration-resistant prostate cancer.
• Zaltrap (ziv-aflibercept) Injection Antiangiogenic therapy for metastatic colorectal cancer.
• Eloxatin (oxaliplatin injection) Platinum-based chemotherapy for colorectal cancer.
• Caprelsa (vandetanib) Tablets Tyrosine kinase inhibitor for medullary thyroid cancer.
• Clolar (clofarabine injection) Nucleoside analog for pediatric acute lymphoblastic leukemia.
• Elitek (rasburicase) Enzyme for tumor lysis syndrome prevention.
• Mozobil (plerixafor) injection Hematopoietic stem cell mobilizer for stem cell transplant.
• Thyrogen (thyrotropin alfa) Thyroid stimulating hormone for thyroid cancer management.
• ALTUVIIIO (Antihemophilic Factor Recombinant, Fc-VWF-XTEN Fusion Protein-ehtl) Long-acting factor VIII replacement therapy for hemophilia A.
• Alprolix (Coagulation Factor IX Recombinant, Fc Fusion Protein) Long-acting factor IX replacement therapy for hemophilia B.
• ELOCTATE (Antihemophilic Factor Recombinant, Fc Fusion Protein) Long-acting factor VIII replacement therapy for hemophilia A.
• Qfitlia (fitusiran) injection Antithrombin-targeting siRNA therapeutic for hemophilia.
• ENJAYMO (sutimlimab-jome) injection Monoclonal antibody for cold agglutinin disease.
• Cablivi (caplacizumab-yhdp) Nanobody therapy for acquired thrombotic thrombocytopenic purpura (aTTP).
• Fabrazyme (agalsidase beta) Enzyme replacement therapy for Fabry disease.
• Aldurazyme (laronidase) Enzyme replacement therapy for mucopolysaccharidosis I (MPS I).
• Lumizyme (alglucosidase alfa) Enzyme replacement therapy for Pompe disease.
• Nexviazyme (avalglucosidase alfa-ngpt) Enzyme replacement therapy for Pompe disease with improved targeting.
• Xenpozyme (olipudase alfa-rpcp) Enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD).
• Cerezyme (imiglucerase) for injection Enzyme replacement therapy for Gaucher disease.
• Cerdelga (eliglustat) capsules Oral substrate reduction therapy for Gaucher disease type 1.
• Toujeo (insulin glargine) injection 300 Units/mL Long-acting insulin analog for diabetes; available in SoloStar and Max SoloStar pen formulations.
• Lantus (insulin glargine injection) 100 Units/mL Long-acting insulin analog for diabetes; available in multiple formulations including SoloStar pen.
• Admelog (insulin lispro injection) 100 Units/mL Rapid-acting insulin analog for diabetes.
• Apidra (insulin glulisine injection) 100 Units/mL Rapid-acting insulin analog for diabetes.
• Tzield (teplizumab-mzwv) injection Disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes; first therapy approved for this indication.
• Soliqua 100/33 (insulin glargine and lixisenatide) injection Combination basal insulin and GLP-1 receptor agonist for diabetes.
• Merilog (insulin aspart-szjj) Injection 100 Units/mL Rapid-acting insulin analog for diabetes.
• Plavix (clopidogrel bisulfate) Antiplatelet agent for cardiovascular disease and stroke prevention.
• Multaq (dronedarone) Antiarrhythmic medication for atrial fibrillation.
• Lovenox (enoxaparin sodium injection) Low molecular weight heparin anticoagulant.
• Praluent (alirocumab) PCSK9 inhibitor for hypercholesterolemia.
• Avapro (irbesartan) ARB medication for hypertension.
• Avalide (irbesartan-hydrochlorothiazide) Combination ARB and diuretic for hypertension.
• Lemtrada (alemtuzumab) Monoclonal antibody for multiple sclerosis.
• Aubagio (teriflunomide) Oral disease-modifying therapy for multiple sclerosis.
• Thymoglobulin (Anti-thymocyte Globulin Rabbit) Immunosuppressive therapy for organ transplant rejection.
• WAYRILZ (rilzabrutinib) tablets Bruton's tyrosine kinase inhibitor for immune thrombocytopenia.
• Rezurock (belumosudil) tablets Rho kinase inhibitor for chronic graft-versus-host disease.
• Synvisc (hylan G-F 20) Viscosupplementation therapy for osteoarthritis of the knee.
• Synvisc-One (hylan G-F 20) Single-injection viscosupplementation therapy for osteoarthritis of the knee.
• Flomax (tamsulosin HCl) Alpha-blocker for benign prostatic hyperplasia.
• Priftin (rifapentine) Tablets Antibiotic for tuberculosis treatment.
• Renvela (sevelamer carbonate) Phosphate binder for end-stage renal disease.
• Hectorol (doxercalciferol) Vitamin D analog for secondary hyperparathyroidism.
• Ferrlecit (sodium ferric gluconate complex in sucrose injection) Iron supplement for iron deficiency anemia.
• Beyfortus (nirsevimab-alip) injection Monoclonal antibody for RSV prevention in infants; co-developed with AstraZeneca.
• MenQuadfi (Meningococcal Groups A C Y W Conjugate Vaccine) Meningococcal conjugate vaccine for protection against four serogroups.

Quantifiable outcome

• Over 600 million medication units produced annually in U.S. facilities
• +3 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature2 records

Partnerships

Ten partnerships are on record, tiered flagship and core.

• Association of Science and Technology Centers (ASTC)flagshipStrategic or Co-development Partner · 1 September 2025Sanofi partnered with ASTC's Seeding Action initiative for The Air We Share program, bringing air quality education to communities through science centers and museums nationwide. The program includes anchor partners The Franklin Institute (Philadelphia), Museum of Science (Boston), and Liberty Science Center (Jersey City), plus 11 additional science centers receiving funding and program resources.
• Discovery EducationcoreStrategic or Co-development PartnerSanofi is a founding member of the Discovery Education STEM Careers Coalition (DESCC), which provides digital content and classroom materials to help students explore STEM-related careers. The program successfully reached 10 million students in 5 years.
• Students 2 SciencecoreStrategic or Co-development PartnerLong-time partnership providing Sanofi mentors to help conduct experiments, career talks, and innovative programming including annual NJ Somerset Patriots STEM in Baseball days reaching more than 10,000 children annually.
• Just-A-Start Biomedical Science Careers ProgramcoreStrategic or Co-development PartnerSanofi supports Just-A-Start's Biomedical Science Careers Program (BSCP) which works to increase inclusion of individuals from all backgrounds in science and medicine while helping health care institutions meet needs for an inclusive workforce.
• Geisinger Commonwealth School of MedicinecoreStrategic or Co-development PartnerSanofi partnered through REACH-HEI (Regional Education Academy for Careers in Health - Higher Education Initiative), an out-of-school program providing academic enrichment including mentoring by medical and graduate students for low-income and/or first-generation-to-college students in northeastern and central Pennsylvania. Participating students achieved 100% college graduation rate.
• RegeneroncoreStrategic or Co-development PartnerCollaboration on Dupixent (dupilumab) and Kevzara (sarilumab) products. Both products are co-developed and marketed through this partnership with shared patent portfolios.
• AstraZenecacoreStrategic or Co-development PartnerCollaboration on Beyfortus (nirsevimab-alip) injection for RSV prevention, with shared patent portfolio.
• TraceLinkcoreTechnology or IntegrationSanofi uses TraceLink's ProductTrack for DSCSA lot-level traceability information storage and recording. All Advanced Shipping Notices (ASNs) containing lot-level DSCSA information are available via EDI and TraceLink portal.
• Antares Vision Group (Track4)coreTechnology or IntegrationSanofi uses Antares' Track4 solution to send and receive GS1 EPCIS data for serial-level traceability compliance under DSCSA requirements.
• Advocacy Community of PracticecoreStrategic or Co-development PartnerSanofi-formed advocacy community for patient advocacy groups to connect, share pragmatic insights, and learn from each other. The community has grown to more than 140 organizations and 250 individuals across various disease states.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novartis: Large-cap pharma with overlapping cardiology, oncology, and immunology franchises, plus a comparable global specialty medicines distribution model.
• Pfizer: Global pharmaceutical company with overlapping vaccines (RSV, meningococcal, influenza), oncology, immunology, and rare disease portfolios that compete head-to-head with Sanofi in U.S. hospital and retail channels.
• Johnson & Johnson Innovative Medicine: Direct peer across oncology (multiple myeloma, prostate cancer), immunology, and pulmonary hypertension, with comparable U.S. hospital and specialty pharmacy channels.
• Roche: Pharmaceutical peer with strong oncology and immunology biologics overlap (multiple myeloma, autoimmune), plus comparable specialty distribution requirements in the U.S.
• AstraZeneca: Strategic Beyfortus (RSV) co-development partner that also competes in oncology and respiratory; shares similar U.S. hospital channel dynamics with Sanofi.
• Eli Lilly: Primary diabetes competitor (Humalog, Trulicity, Mounjaro) competing directly with Sanofi's Lantus/Toujeo/Admelog/Soliqua portfolio across U.S. payors and prescribers.
• Novo Nordisk: Largest direct competitor in insulin and broader diabetes care, with overlapping U.S. field-sales and payor contracting motions against Sanofi's diabetes franchise.
• Bristol-Myers Squibb: Direct oncology competitor (multiple myeloma franchise with Empliciti/Pomalyst) and immunology presence, sharing the same physician and hospital channel customers.
• GSK: Global vaccines competitor with overlapping meningococcal, RSV and influenza portfolios, plus an established U.S. specialty pharma distribution network.
• Merck & Co. Major oncology and vaccines competitor (Keytruda, Gardasil) whose hospital and specialty distribution footprint directly parallels Sanofi's U.S. field sales model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about sanofi-aventis usa (all divisions)